slides · global inventory
Table
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 60,568
Current window 43,441-43,470
Pages 2,019
Rows per page 30
Component
43,441-43,470 of 60,568
49
Kering | Investor Presentation Deck | 63 slidesKering | Investor Presentation Deck | 63 slides · Kering
Conference presentation Investor relations 1 hit
52
Kering | Investor Presentation Deck | 63 slidesKering | Investor Presentation Deck | 63 slides · Kering
Conference presentation Investor relations 1 hit
55
The slide uses a high-fashion image as a visual anchor for the segment.Kering | Investor Presentation Deck | 63 slides · Kering
Conference presentation Investor relations 1 hit
57
Includes a waterfall chart for revenue growth and a summary table for operating income and CAPEX.Kering | Investor Presentation Deck | 63 slides · Kering
Conference presentation Investor relations 1 hit
58
The table highlights key income statement metrics including revenue, margins, and net income.Kering | Investor Presentation Deck | 63 slides · Kering
Conference presentation Investor relations 1 hit
59
The table compares standard H1 2023/2022 figures with an adjusted H1 2023 column.Kering | Investor Presentation Deck | 63 slides · Kering
Conference presentation Investor relations 1 hit
61
Values are in millions of Euros (€M).Kering | Investor Presentation Deck | 63 slides · Kering
Conference presentation Investor relations 1 hit
06
The slide uses a standard pharmaceutical pipeline table format.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations Beat · Solution1 hit
09
Includes a mechanism of action diagram, a market data table, and a comparison of current therapy limitations.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
11
Includes both a longitudinal line chart of IRAK4 reduction and a grouped bar chart with a summary table for cytokine inhibition.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
15
The slide includes a disclaimer regarding the non-head-to-head nature of the comparison.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
17
The slide includes a disclaimer regarding the non-head-to-head nature of the comparison.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
18
The slide highlights a favorable safety profile with no serious adverse events (SAEs) or drug-related infections.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
22
Includes a table of prevalence/incidence for various indications and a diagram of the JAK-STAT signaling pathway.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
24
The slide uses a process flow diagram to illustrate the dose escalation (0.05 to 0.40 mg/kg) leading to MTD/RP2D expansion into four specific patient cohorts.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
25
The table displays adverse events occurring in 2 or more patients. Data includes patient counts and percentages for both 'All' and 'Related' adverse events.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
26
Includes a line chart showing plasma concentration over time and a table summarizing PK parameters (Cmax, AUClast, Vd, CL, t1/2).Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
33
Includes three dose-response curves and a comparative table of clinical stage and potency metrics.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
35
Includes a visual representation of the dose escalation study design and a detailed table of patient baseline characteristics.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
36
The slide combines a biological mechanism diagram with clinical trial data (table and line chart) to validate the drug's mechanism of action.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
09
Details the dosing schedule (13 days) and specific sampling days for buccal cells, skin, and platelets across three dose levels.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
11
The slide outlines the methodology for a clinical trial, specifically focusing on the 28-day treatment schedule and cohort details.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
17
The slide highlights the unique 'Protein replacement' approach of Nomlabofusp compared to other modalities like Mitochondrial Oxidative Stress Modifiers, Gene Expression Regulators, Pathway Modifiers, and Gene Therapy.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
26
The slide details the dosing schedule (13 days) and specific sampling days for buccal cells, skin, and platelets across three dose cohorts (25mg, 50mg, 100mg).Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
28
The table displays n (%) for categorical variables and descriptive statistics (mean, SD, median, range) for age.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
29
MAD likely stands for Multiple Ascending Dose.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
33
The slide outlines a 28-day treatment schedule with specific administration days highlighted in green.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
36
The slide highlights that demographics are similar between Phase 1 and Phase 2 trials.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
37
Data presented as n, mean (SD), median, Q1/Q3, and min/max.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
08
The chart shows a stacked bar breakdown of U.S. vs EU sales over 6 quarters.Legend Biotech | Results Presentation Deck | 15 slides · Legend Biotech
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit